TrialOrphanet journal of rare diseases2018

How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial.

Murtuza Bharmal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.